Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesFDA actions in brief, June 2009 (Avastin, Azor, Exforge HCT, Cycloset, ACTOplus met XR, Lamictal ODT, Dysport, Creon)
Formulary , 06/11/09
Bevacizumab was approved for use as a single agent for the treatment of patients with progressive glioblastoma after prior therapy. The combination of amlodipine and olmesartan was approved for first-line therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections
Sanofi-aventis, 12/17/09
Telmisartan/amlodipine: approved for high blood pressure
Formulary , 12/16/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Generic drugs dominate market, look to expand into biologics
Formulary , 12/16/09
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor